Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-127-35 targeted active specific immunotherapy

International Journal of Cancer

Volumn 115, Issue 2, 2005, Pages 248-255

  Von Holzen, Urs ^a   Adamina, Michel ^a   Bolli, Martin ^a   Weber, Walter P ^a   Zajac, Paul ^a   Groeper, Celia ^a   Reschner, Anca ^a   Feder, Chantal ^a   Schumacher, Reto ^a   Marti, Walter ^a   Oertli, Daniel ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ZLF   (Switzerland)

Author keywords

CTL; IL 15; IL 2; IL 7; Melanoma immunotherapy

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; COMMON RECEPTOR GAMMA CHAIN; CYTOKINE; HLA A0201 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; MART 1 [27-35]; MELAN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION; VACCINATION;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HLA-A ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-7; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 20944438011     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20858     Document Type: Article

References (45)

1. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
2. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide or tumor lysate -pulsed dendritic cells. Nat Med 1998;4:328-32.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-27.
4. Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Gueller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G. Phase I/II clinical trial of a non replicative vaccinia virus expressing multiple HLA-A0201 restricted tumor associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003;14:1497-510.
5. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;4:251-62.
6. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol 2003;4:225-34.
7. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM. Roles of tumour localization, second signals and cross-priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
8. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-6.
9. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
10. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nature Rev Immunol 2003;3:269-79.
11. Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC, Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 2002;13:569-75.
12. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 1998;77:538-42.
13. Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A, Zuber M, Luscher U, Harder F, Heberer M. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 1995;64:309-15.
14. Noppen C, Levy F, Burri L, Zajac P, Remmel E, Schaefer C, Luscher U, Heberer M, Spagnoli GC. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer 2000;87:241-6
15. Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 1996;183:2403-7.
16. Hörig H, Spagnoli GC, Filgueira L, Babst R, Gallati H, Harder F, Juretic A, Heberer M. Exogenous glutamine requirement is confined to late events of T cell activation. J Cell Biochem 1993;53: 343-51.
17. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
18. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector and memory immune responses. Annu Rev Immunol 2000;18:593-620.
19. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Förster R, Rowland-Jones S, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001;410:106-11.
20. Appay V, Dunbar R, Callan M, Klenerman P, Gillespie GMA, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Med 2002;8:379-85.
21. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-32.
22. Berard M, Brandt K, Bulfone Paus S, Tough DF. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol 2003;170:5018-26.
23. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, et al. Vaccination with mage-3A1 peptide pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
24. Smith JWII, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dois A, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003;21:1562-73.
25. Mocarski ES Jr, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM, Eds. Fields virology, 4th ed., Philadelphia: Lippincott, Williams and Wilkins. 2001.
26. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002;99:3892-904.
27. Lynch DH, Miller RE. Interleukin 7 promotes long term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med 1994;179:31-42.
28. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998; 77:1907-16
29. Kieper WC, Tan JT, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R, Surh CD. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med 2002;195:1533-9.
30. Prlic M, Lefrancois L, Jameson SC. Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL-7) and IL-15. J Exp Med 2002;195:49-52.
31. Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common γ-chain cytokines. J Immunol 2003;171:2134-41.
32. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 2000;288:675-8.
33. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000;97:11445-50.
34. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001;14:105-10.
35. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
36. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, Mackensen A. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 2003;170:2161-9.
37. Blattmann JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nature Med 2003;9:540-7.
38. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998;8:591-9.
39. Goldrath AW, Sivakumar PV, Glaccum M, Kennedy MK, Bevan MJ, Benoist C, Mathis D, Butz E. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 2002;195:1515-22.
40. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002;195:1523-32.
41. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double -stranded RNA or lypopolysaccharide and promotes dendritic cell activation. J Immunol 2001;167:1179-87.
42. Le Bon A, Schiavoni G, D'Agostino G, Gresser J, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70.
43. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E, Tough D, Donatelli I, et al. Type I IFN as a natural adjuvant for a protective immune response. J Immunol 2002;169:375-83.
44. Rizza P, Ferrantini M, Capone I, Belardelli F. Cytokines as natural adjuvants for vaccines: where are we now? Trends Immunol 2002;23:381-3.
45. Belardelli F, Ferrantini M, Santini SM, Baccarini S, Proietti E, Colombo MP, Sprent J, Tough DF. The induction of in vivo proliferation of long-lived CD44high CD8+ T cells after the injection of tumor cells expressing IFN-α1 into syngeneic mice. Cancer Res 1998;58:5795-802.